Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Document Type
Year range
International Transaction Journal of Engineering Management & Applied Sciences & Technologies ; 13(8), 2022.
Article in English | Web of Science | ID: covidwho-2025681


The Electronic Clinical Pharmacologist (ECP) is a Medical Decision Support System (MDSS). This system is based on the Unified Medical Knowledge Base (UMKB), which is updated and updated as new medicines are released and specialized publications are published in peer-reviewed biomedical scientific journals. ECP helps to reduce the risks of medical errors and complications in clinical practice. When using ECP, the number of side effects from the use of medicines decreases, the patient's admission time is reduced, the quality of medical care is improved, the costs of the medical organization for the purchase of medicines are reduced, all this is carried out due to more rational prescriptions of the doctor. The ECP takes into account the personalized approach of drug therapy. Based on Stavropol State Medical University and medical universities of the North Caucasus Federal District, a questionnaire of students was conducted among students of 3-6 courses, as well as testing of the ECP application to compare treatment standards (clinical recommendations) according to the clinical recommendations of the Ministry of Health (outpatient, inpatient treatment) and self-treatment of students and their relatives. And patterns of changes in the course of treatment were also revealed when using MDSS ECP and without it. (C) 2022 INT TRANS J ENG MANAG SCI TECH.

Medical News of North Caucasus ; 17(2):208-211, 2022.
Article in English | Scopus | ID: covidwho-2025667


The study presents a clinical case of treating acute myeloid leukemia with an unfavorable genetic prognosis due to genotyping by high-throughput sequencing. The patient underwent related allogeneic bone marrow transplantation with targeted chemotherapy. The disease manifested itself after a new coronavirus infection. Mutations R140Q in the IDH2 gene and P799S in the DNMT3A gene were detected by high throughput sequencing. Given the unfavorable genetic prognosis, bone marrow transplantation from an HLA-compatible sibling was performed. On day 22, COVID-19 was detected, and ruxolitinib was added to the treatment. On the 25th day, hematopoiesis was restored with the preservation of clinical and hematological remission. Ten months after transplantation, a relapse was diagnosed, for which the patient started targeted therapy with 5-azacytidine with venetoclax in combination with transfusions of donor leukocytes. The second remission was achieved after the first course. The total duration of follow-up was 24 months. © Group of authors, 2022.